Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001626971

P/B 10.34

P/E -49.24

P/S 0.00

Market Cap 742.22 Mn

ROIC (Qtr) -50.43

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 1.01 Mn

Debt/Equity (Qtr) 0.01

About

Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company that operates in the biotechnology industry. With a focus on the development of immune modulator product candidates, the company aims to treat a range of diseases including solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Corvus Pharmaceuticals' lead product candidate, soquelitinib, is a selective, covalent inhibitor of ITK, an enzyme that plays a key role in T cell signaling and differentiation. Corvus Pharmaceuticals' main business...

Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company that operates in the biotechnology industry. With a focus on the development of immune modulator product candidates, the company aims to treat a range of diseases including solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Corvus Pharmaceuticals' lead product candidate, soquelitinib, is a selective, covalent inhibitor of ITK, an enzyme that plays a key role in T cell signaling and differentiation.

Corvus Pharmaceuticals' main business activities revolve around the development of novel, targeted therapies for the treatment of various diseases. The company's operations span across the United States, Australia, China, and South Korea, where it conducts clinical trials for its product candidates. Corvus Pharmaceuticals' expertise in immunology and oncology has enabled it to develop a diverse and versatile product pipeline.

The company generates revenue through the development and commercialization of its product candidates. Its primary products include soquelitinib, ciforadenant, and mupadolimab, which are being evaluated in clinical trials. Soquelitinib is an orally bioavailable compound that has demonstrated anti-tumor activity in preclinical studies and is currently being evaluated in a Phase 1/1b clinical trial in patients with advanced, refractory T cell lymphomas. Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine, which is designed to disable a tumor's ability to subvert attack by the immune system. Mupadolimab is a humanized monoclonal antibody that is designed to react with a specific site on CD73, an enzyme that is involved in the regulation of immune responses.

Corvus Pharmaceuticals is well-positioned within the industry, boasting a strong management team with a track record of developing successful biotechnology companies. Its competitive advantages lie in its expertise in immunology and oncology, its diverse and versatile product pipeline, and its ability to develop novel, targeted therapies.

The company's customers include the Kidney Cancer Research Consortium, which is collaborating with Corvus Pharmaceuticals on the development of ciforadenant. Corvus Pharmaceuticals also has a number of partners, including Angel Pharmaceuticals Co. Ltd., which is developing mupadolimab in China.

In terms of brand names, Corvus Pharmaceuticals has a number of product candidates in its pipeline, including soquelitinib, ciforadenant, and mupadolimab. The company also has a license agreement with Vernalis, which grants Corvus Pharmaceuticals an exclusive, worldwide license under certain patent rights and know-how to develop and commercialize products containing certain adenosine receptor antagonists, including ciforadenant. Additionally, Corvus Pharmaceuticals has a license agreement with Scripps, which grants the company a non-exclusive, world-wide license under certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma.

Stock Price Chart

Analysis

Pros

Healthy cash reserves of 2.87M provide 7.56x coverage of short-term debt 379000, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 80.47M provides 79.60x coverage of total debt 1.01M, indicating robust asset backing and low credit risk.
Long-term investments of 11.53M provide solid 18.24x coverage of long-term debt 632000, indicating strategic financial planning.
Operating cash flow of (32.07M) provides strong 6414.20x coverage of operating expenses (5000), showing operational efficiency.
Short-term investments of 62.82M provide solid 10.98x coverage of other current liabilities 5.72M, indicating strong liquidity.

Cons

Investment activities of (24.76M) provide weak support for R&D spending of 29.75M, which is -0.83x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Short-term investments of 62.82M significantly exceed cash reserves of 2.87M, which is 21.91x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
The company's operating cash flow of (32.07M) shows concerning coverage of stock compensation expenses of 4.57M, with a -7.02 ratio indicating potential earnings quality issues.
Free cash flow of (32.22M) provides weak coverage of capital expenditures of 144000, with a -223.72 ratio suggesting additional external financing needs for growth initiatives.
Operating earnings of (15.07M) show weak coverage of depreciation charges of 99000, with a -152.27 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	9.05	12.31
EV to Cash from Ops.	-22.72	23.25
EV to Debt	720.69	738.44
EV to EBIT	-48.33	-9.16
EV to EBITDA	-18.80	6.95
EV to Free Cash Flow [EV/FCF]	-22.62	21.90
EV to Market Cap	0.98	65.67
EV to Revenue	0.00	227.32
Price to Book Value [P/B]	10.34	22.34
Price to Earnings [P/E]	-49.24	-11.77

Dividend Metrics

Metric	Value	Industry	Percentile
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	0.00	-27.13
Cash and Equivalents Growth (1y) %	-38.74	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	73.47	-46.93
EBITDA Growth (1y) %	-55.01	-1.68
EBIT Growth (1y) %	73.47	-56.45
EBT Growth (1y) %	73.47	-12.70
EPS Growth (1y) %	81.52	-28.31
FCF Growth (1y) %	-45.60	-31.90
Gross Profit Growth (1y) %	0.00	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	0.36	3.85
Current Ratio	8.29	7.27
Debt to Equity Ratio	0.01	0.40
Interest Cover Ratio	0.00	841.00
Times Interest Earned	0.00	841.00

Profitability

Metric	Value	Industry	Percentile
EBITDA Margin %	0.00	-18,234.31
EBIT Margin %	0.00	-18,580.80
EBT Margin %	0.00	-19,488.74
Gross Margin %	0.00	-7.59
Net Profit Margin %	0.00	-19,439.22

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)